No Data
No Data
Express News | Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025
Inhibikase Therapeutics | 10-K/A: Annual report (Amendment)
Inhibikase Therapeutics Advances PAH Treatment With New Leadership
Inhibikase Names McIntyre Finance Chief as Lees-Rolfe Resigns
Press Release: Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Hedge Funds Owners May Consider Drastic Measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) Recent US$29m Drop Adds to Long-term Losses